PET Imaging of Patients with Non-small Cell Lung Cancer Employing an EGF Receptor Targeting Drug As Tracer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Nov 19

PMID 22095231

Citations 32

Authors

A A Memon

B Weber

M Winterdahl

S Jakobsen

P Meldgaard

H H T Madsen

S Keiding

E Nexo

B S Sorensen

Affiliations

Soon will be listed here.

Abstract

Background: We have previously developed (11)C-erlotinib as a new positron emission tomography (PET) tracer and shown that it accumulates in epidermal growth factor receptor (EGFR)-positive lung cancer xenografts in mice. Here, we present a study in patients with non-small cell lung cancer (NSCLC) investigating the feasibility of (11)C-erlotinib PET as a potential method for the identification of lung tumours accumulating erlotinib.

Methods: Thirteen patients with NSCLC destined for erlotinib treatment were examined by contrast-enhanced computed tomography (CT), (11)C-erlotinib PET/low-dose CT and (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/low-dose CT before start of the erlotinib treatment. After 12 weeks treatment, they were examined by (18)F-FDG PET/contrast-enhanced CT for the assessment of clinical response.

Results: Of the 13 patients included, 4 accumulated (11)C-erlotinib in one or more of their lung tumours or lymph-node metastases. Moreover, (11)C-erlotinib PET/CT identified lesions that were not visible on (18)F-FDG PET/CT. Of the four patients with accumulation of (11)C-erlotinib, one died before follow-up, whereas the other three showed a positive response to erlotinib treatment. Three of the nine patients with no accumulation died before follow-up, four showed progressive disease while two had stable disease after 12 weeks of treatment.

Conclusion: Our data show a potential for (11)C-erlotinib PET/CT for visualizing NSCLC lung tumours, including lymph nodes not identified by (18)F-FDG PET/CT. Large clinical studies are now needed to explore to which extent pre-treatment (11)C-erlotinib PET/CT can predict erlotinib treatment response.

Citing Articles

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients - an overview.

Van De Stadt E, Yaqub M, Jahangir A, Hendrikse H, Bahce I Front Oncol. 2022; 12:900450.

PMID: 36313723 PMC: 9597357. DOI: 10.3389/fonc.2022.900450.

Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose.

Zhu J, Pan F, Cai H, Pan L, Li Y, Li L Front Med (Lausanne). 2022; 9:945602.

PMID: 36275809 PMC: 9581209. DOI: 10.3389/fmed.2022.945602.

PET Imaging of EGFR Expression: An Overview of Radiolabeled EGFR TKIs.

Zhu J, Li Y, Wu X, Li Y, Wang L, Fan H Curr Top Med Chem. 2022; 22(28):2329-2342.

PMID: 36056825 DOI: 10.2174/1568026622666220903142416.

Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.

Galldiks N, Langen K, Albert N, Law I, Kim M, Villanueva-Meyer J Neuro Oncol. 2022; 24(11):1815-1826.

PMID: 35674736 PMC: 9629449. DOI: 10.1093/neuonc/noac131.

The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.

Hognasbacka A, Poot A, Vugts D, van Dongen G, Windhorst A Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455447 PMC: 9033078. DOI: 10.3390/ph15040450.

References

Su H, Seimbille Y, Ferl G, Bodenstein C, Fueger B, Kim K . Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008; 35(6):1089-99. DOI: 10.1007/s00259-007-0636-6. View

Wang J, Gao M, Miller K, Sledge G, Zheng Q . Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2006; 16(15):4102-6. DOI: 10.1016/j.bmcl.2006.04.080. View

Morgillo F, Kim W, Kim E, Ciardiello F, Hong W, Lee H . Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007; 13(9):2795-803. DOI: 10.1158/1078-0432.CCR-06-2077. View

Eberhard D, Johnson B, Amler L, Goddard A, Heldens S, Herbst R . Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25):5900-9. DOI: 10.1200/JCO.2005.02.857. View

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21(12):2237-46. DOI: 10.1200/JCO.2003.10.038. View

Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S . Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993; 53(10 Suppl):2379-85. View

Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A . Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009; 361(1):32-9. DOI: 10.1056/NEJMoa0900043. View

Zhang M, Kumata K, Hatori A, Takai N, Toyohara J, Yamasaki T . [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma. Mol Imaging Biol. 2009; 12(2):181-91. DOI: 10.1007/s11307-009-0265-5. View

Love C, Tomas M, Tronco G, Palestro C . FDG PET of infection and inflammation. Radiographics. 2005; 25(5):1357-68. DOI: 10.1148/rg.255045122. View

10.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

11.

Sequist L, Bell D, Lynch T, Haber D . Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007; 25(5):587-95. DOI: 10.1200/JCO.2006.07.3585. View

12.

Jerusalem G, Hustinx R, Beguin Y, Fillet G . PET scan imaging in oncology. Eur J Cancer. 2003; 39(11):1525-34. DOI: 10.1016/s0959-8049(03)00374-5. View

13.

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

14.

Weber B, Winterdahl M, Memon A, Sorensen B, Keiding S, Sorensen L . Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011; 6(7):1287-9. DOI: 10.1097/JTO.0b013e318219ab87. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Cohen M, Johnson J, Chen Y, Sridhara R, Pazdur R . FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005; 10(7):461-6. DOI: 10.1634/theoncologist.10-7-461. View

17.

Gambhir S . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. DOI: 10.1038/nrc882. View

18.

Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11):1160-74. DOI: 10.1056/NEJMra0707704. View

19.

Rohren E, Turkington T, Coleman R . Clinical applications of PET in oncology. Radiology. 2004; 231(2):305-32. DOI: 10.1148/radiol.2312021185. View

20.

Memon A, Jakobsen S, Dagnaes-Hansen F, Sorensen B, Keiding S, Nexo E . Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res. 2009; 69(3):873-8. DOI: 10.1158/0008-5472.CAN-08-3118. View